Page 53 - ISMCON souvenir 2021

ISMSCON - 2021

OS13: Association of Leptin with Polycystic Ovary Syndrome:
A Systematic Review and Meta-Analysis

Shreya Gulati Amit Kumar Dimple Rawat Aradhana Rohini Sehgal Rinchen Zangmo Vivek Dixit
Premlata Arti Gulati
Presenter :Aradhana Kumari
Clinical Epidemiology Unit, All India Institute of Medical Sciences, New Delhi, India Department of Orthopaedics,
J.J.M Medical College, Davanagere, Karnataka, India Dr. Ram Manohar Lohia Hospital, New Delhi, India
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India Department of Obstetrics and
Gynaecology, All India Institute of Medical Sciences, New Delhi, India Department of Orthopaedics, All India
Institute of Medical Sciences, New Delhi, India
Received: 2 February 2021 / Accepted: 28 May 2021
Keywords Leptin PCOS Polycystic ovary syndrome Adipokine

Abstract
Background Serum leptin has been considered as an important measurable diagnostic and prognostic
biomarker for polycystic ovarian syndrome (PCOS), AQ1 although its evidence to use in clinical practice
is limited. We aim to synthesize the available evidence on the clinical use of serum leptin values in PCOS
by doing a systematic review and meta-analysis of studies.
Objective To conduct a meta-analysis to determine the pooled effect size of the association of leptin
levels in patients with PCOS.
Methods We searched electronic databases, i.e., PubMed, Google Scholar, Web of Science, ClinicalTrials.
gov, and Medline from inception to September 2020, AQ3 keeping filters for human studies and published
in the English language. We used the random-effects model if between the studies heterogeneity was
> 50%; otherwise, AQ4 a fixed-effect model was applied to determine the standardized mean difference
with 95% CI for comparison of leptin level between cases and controls. AQ5 All the statistical analyses
were completed using software STATA version 13.
Results The meta-analysis included a total of 35 studies involving 2015 cases and 1767 controls that
suggested statistically significantly higher leptin levels in the women with PCOS compared to controls
(SMD, 1.76, 95% CI 1.28 to 2.23, P < 0.001). In the stratified analysis including only high methodological
quality studies, we did not observe a statistically significant difference in the leptin level between PCOS
and controls (SMD 0.68, 95% CI −0.09 to 1.46). Analysis restricted to low methodological quality studies
observed statistically significantly high leptin levels in PCOS women compared to controls (SMD 2.24,
95% CI 1.65 to 2.83).
Conclusion The available evidence suggests that elevated leptin levels may be associated with the risk
of PCOS compared to controls; however, failure to observe the similar association in high methodological
quality studies demands further well-designed adequately powered studies to validate the findings.

CONFERENCE SOUVENIR 51